Forte Biosciences, Inc. 8K

Forte Biosciences, Inc. reported positive, statistically significant Phase 1b efficacy and safety data for its vitiligo drug candidate FB102 in a double‑blind, placebo‑controlled study, indicating a promising profile for further clinical development.

Forte Biosciences, Inc. furnished a presentation as Exhibit 99.2 describing Phase 1b clinical trial results for its vitiligo candidate FB102, showing that in a 43-patient double‑blind, placebo‑controlled study, FB102 achieved statistically significant improvements in facial vitiligo area scoring index (FVASI) versus placebo by week 24 (approximately 30% mean improvement overall and 43% in patients with higher baseline disease involvement), with early onset of effect by day 64, meaningful FVASI50 and FVASI75 responder rates, and a favorable safety profile limited to mild to moderate adverse events and no severe events, supporting continued development of FB102 for vitiligo.

Filing Facts

CIK

1419041

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-299177

Alert Tier

6